Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 243 results found. Search for [ Pfizer COVID-19 vaccine trials india ]

Results 1 to 21 of 243
PTI
January 16, 2021
Speaking at the 25th Wharton India Economic Forum, he said the Indian pharma industry ensured the continuity of supplies


Reuters
January 14, 2021
As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial, said Niti Aayog member VK Paul who also heads National Expert Group On Vaccine Administration for COVID-19 (NEGVAC)


BusinessToday.In
January 12, 2021
Among these vaccines are those developed by Zydus Cadila, Biological E and Gennova, along with Russia's Sputnik-V vaccine


Rajeev Dubey | Vivek Punj
January 11, 2021
Full authorisation-better known as \"full pre-qualification\"-is a pre-requisite to sell the vaccine in the open market or for mass immunisation of healthy individuals who are not frontline workers


Associated Press
January 8, 2021
Speaking during a news conference in Brussels on Friday, European Commission president Ursula von der Leyen said the agreement will double the amount of doses already ordered by the 27-nation bloc


Joe C Mathew
January 7, 2021
Fact sheets for recipients of Moderna and Pfizer-BioNTech vaccines in US and UK clarify that the vaccines are yet to be fully approved; recipients have been asked to get help if they experience severe side effects or allergic reactions


PTI
January 6, 2021
(For) all our vaccines, we are looking at right now..(we) are targeting 2-8 degree because our logistics are worked out on that basis and we are working on that, DBT secretary Renu Swarup said at a press briefing


Manoj Sharma
January 5, 2021
There was immense pressure on governments to develop a vaccine at the earliest due to the destruction COVID-19 pandemic was unleashing. This led to a race among pharma companies to be the first to develop a vaccine


Reuters
January 4, 2021
Scientists say the new South African variant has multiple mutations in the important \"spike\" protein that the virus uses to infect human cells


BusinessToday.In
January 4, 2021
Bharat Biotech's Chairman and Managing Director Dr. Krishna Ella, in a press conference on Monday, January 5, clarified that its vaccine is safe and the company is conducting trials in over 12 countries besides India


BusinessToday.In
January 4, 2021
Defending Covaxin, the Bhart Biotech Chairman said that his company has tremendous experience in developing vaccines; more than 70 articles on data related to Covaxin have been published in various journals


Reuters
January 4, 2021
Six hospitals in England will administer the first of around 530,000 doses Britain has ready


Reuters
January 3, 2021
COVID-19 vaccine: The ministry added that the doctor has a history of allergic reactions and said that there is no evidence from clinical trials that anyone has developed an inflammation of the brain after the vaccine's application


BusinessToday.In
January 2, 2021
Covishield DCGI approval: Pune-based Serum Institute will have to provide safety, efficacy and immunogenicity data from the ongoing clinical trials in India and globally


BusinessToday.In
January 1, 2021
Covishield has become the first coronavirus vaccine to receive a regulatory nod in India. Now, Drug Controller General of India (DCGI) will take a final call on rolling out the inoculation


BusinessToday.In
December 30, 2020
The expert committee on COVID-19 analysed the additional data and information that it had asked from SII and Bharat Biotech earlier this month


PTI
December 30, 2020
As per the report, Matthew's condition has improved since his symptoms peaked on Christmas Day but still feels fatigued


BusinessToday.In
December 30, 2020
This development comes hours after the UK government accepted the recommendation from the Medicines and Healthcare Regulatory Agency (MHRA) to authorise Oxford University-AstraZeneca's Covid-19 vaccine, named Covishield, for emergency use


BusinessToday.In
December 30, 2020
Oxford-AstraZeneca vaccine approved: The world's largest vaccine maker by volume, Serum Institute has already manufactured 50 million doses of Oxford-AstraZeneca vaccine on at-risk funding; the vaccine is cheap and easy to produce


BusinessToday.In
December 29, 2020
Serum Institute of India (SII) CEO Adar Poonawalla said on December 28, that the vaccine is likely to get an emergency-use licence from the UK Medicines and Healthcare products Regulatory Agency as well as the Indian regulator, Drugs Controller General of India (DCGI), by early January


PAGES 1 OF 13  12345